Literature DB >> 31271737

Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.

Pimsiri Sripongpun1, Ajitha Mannalithara2, Paul Y Kwo2, W Ray Kim3.   

Abstract

Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment. In its registrations trials, TAF demonstrated better renal safety and improvement in alanine aminotransferase (ALT) activities compared with tenofovir disoproxil fumarate (TDF).1-3 However, data are scarce regarding these outcomes in liver transplantation (LTx) recipients.4 In this study, we determine effects of switching from other antivirals to TAF on ALT and renal function in LTx recipients.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID： 31271737     DOI： 10.1016/j.cgh.2019.05.057

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  5 in total

1.  Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients.

Authors:  Joanne K Liu; Philip Vutien; Daniel Q Huang; Masatoshi Ishigami; Charles S Landis; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-03       Impact factor: 13.576

2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

Review 3.  Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

Authors:  Ilaria Lenci; Martina Milana; Giuseppe Grassi; Tommaso M Manzia; Carlo Gazia; Giuseppe Tisone; Roberta Angelico; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2020-05-14       Impact factor: 5.742

Review 4.  An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.

Authors:  Michael R Charlton; Altaf Alam; Akash Shukla; Bekhbold Dashtseren; Cosmas Rinaldi Adithya Lesmana; Davadoorj Duger; Diana Alcantara Payawal; Do Duy Cuong; Ganbolor Jargalsaikhan; Ian Homer Yee Cua; Jose Decena Sollano; Karam Romeo Singh; Kaushal Madan; Khin Maung Win; Khin Pyone Kyi; Kyaw Soe Tun; Mohd Salih; Mukul Rastogi; Neeraj Saraf; Pham Thi Thu Thuy; Pham Tran Dieu Hien; Rino Alvani Gani; Rosmawati Mohamed; Tawesak Tanwandee; Teerha Piratvisuth; Wattana Sukeepaisarnjaroen; Win Naing; Zahid Yasin Hashmi
Journal:  J Gastroenterol       Date:  2020-07-14       Impact factor: 7.527

Review 5.  Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.

Authors:  Young-Suk Lim; Wai-Kay Seto; Masayuki Kurosaki; Scott Fung; Jia-Horng Kao; Jinlin Hou; Stuart C Gordon; John F Flaherty; Leland J Yee; Yang Zhao; Kosh Agarwal; Pietro Lampertico
Journal:  Aliment Pharmacol Ther       Date:  2022-02-17       Impact factor: 9.524
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.